EUCTR2013-004890-28-IT进行中（未招募）1 期
A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplant (HSCT) Consolidation.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 326
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of written informed consent approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) with privacy language in accordance with national regulations (e.g., HIPAA authorization for US sites) prior to any study-related procedures, including withdrawal of prohibited medications if applicable.
- •2. Age =18 years at the time of informed consent.
- •3. Morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS), as defined by World Health Organization criteria, as determined by pathology review at the study site.
- •4. Refractory or relapsed AML after first-line therapy, with or without HSCT. First-line therapy can consist of 1 or 2 induction blocks, and must have included at least 1 cycle of an anthracycline/mitoxantrone-containing induction block at a standard dose.
- •Refractory to first-line therapy is defined as:
- •After 1 cycle, lack of achievement of CR, CRp, or CRi and a reduction in bone marrow blasts of less than 50%.
- •After 2 cycles, lack of achievement of CR, CRp, or CRi.
- •Relapse within 6 months or less after first-line therapy is defined as (all criteria must be met):
- •Achievement of CR, CRi, or CRp, as defined by 2003 International Working Group criteria (Section 8.2) after initial AML therapy with or without consolidation or maintenance, and with or without HSCT as consolidation
- •Duration of CR, CRi or CRp is measured from the date of the bone marrow assessment which confirmed response to the date of the bone marrow assessment that identified relapse or the appearance of peripheral blasts
- •5. Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood (allelic ratio as determined by a central laboratory with a cutoff of >3% FLT3ITD/total FLT3).
- •6. Eligibility for pre-selected salvage chemotherapy, according to the Investigator’s assessment.
- •7. ECOG performance score 0-2.
- •8. Discontinuation of prior AML treatment before the start of study treatment (except hydroxyurea, which is permitted for blast control up to the day of starting study treatment) for at least 2 weeks for cytotoxic agents, or for at least 5 half-lives for non cytotoxic agents.
- •9. Serum creatinine =1.5×upper limit of normal (ULN), or glomerular filtration rate >25 mL/min/1.73m2, as calculated with the modified Cockcroft-Gault formula.
- •10. Serum potassium, magnesium, and calcium (serum calcium corrected for hypoalbuminemia) within institutional normal limits. Subjects with electrolytes outside the normal range will be eligible if these values are corrected upon retesting following any necessary supplementation.
- •11. Total serum bilirubin =1.5×ULN.
- •12. Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) =2.5×ULN.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 326
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Acute promyelocytic leukemia (AML subtype M3).
- •2. AML secondary to prior chemotherapy for other neoplasms, except AML secondary to prior MDS.
- •3. History of another malignancy, unless the candidate has been disease-free for at least 5 years.
- •Candidates with treated non-melanoma skin cancer, carcinoma in situ, or cervical intraepithelial neoplasia are eligible regardless of the time spent disease-free, if they have completed definitive treatment.
- •Candidates with organ-confined prostate cancer, with no evidence of recurrent or progressive disease, are eligible if hormonal therapy has been begun, or if thetumor has been surgically removed or treated with definitive radiotherapy.
- •4. Persistent, clinically significant > Grade 1 non-hematologic toxicity from prior AML therapy.
- •5. Clinically significant GVHD or GVHD requiring initiation of treatment or treatment escalation within 21 days, and/or > Grade 1 persistent or clinically significant nonhematologic toxicity related to HSCT.
- •6. History of, or current, central nervous system involvement with AML.
- •7. Clinically significant coagulation abnormality, such as disseminated intravascular coagulation.
- •8. Prior treatment with quizartinib or participated in a prior quizartinib study.
- •9. Known presence of a FLT3-D835 mutation at study enrollment. For a candidate who has received prior FLT3-targeted therapy (with the exception of midostaurin), the absence of a FLT3-D835 mutation at study enrollment must be documented.
- •10. Major surgery within 4 weeks prior to screening.
- •11. Radiation therapy within 4 weeks prior to screening.
- •12. Uncontrolled or significant cardiovascular disease, including:
- •QTcF interval >450 ms (average of triplicate determinations).
- •Diagnosed or suspected long QT syndrome, or known family history of long QT syndrome.
- •History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or torsade de pointes.
- •History of second or third degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers, and have no history of fainting or clinically relevant arrhythmia with pacemakers.
- •Myocardial infarction within 6 months prior to screening.
- •Uncontrolled angina pectoris within 6 months prior to screening.
- •New York Heart Association (NYHA) Class 3 or 4 congestive heart failure.
- •Left ventricular ejection fraction (LVEF) =45% or institutional lower limit of normal.
- •Uncontrolled hypertension.
- •Complete left or right bundle branch block.
- •13. Active infection not well controlled by antibacterial or antiviral therapy.
- •14. Known infection with human immunodeficiency virus, or active hepatitis B or C, or other active clinically relevant liver disease.
- •15. Unwillingness to receive infusion of blood products according to the protocol.
- •16. In a man whose sexual partner is a woman of childbearing potential, unwillingness or inability to use an acceptable contraceptive method for the entire study period and for at least 3 months after study completion.
- •17. In a woman of childbearing potential, unwillingness or inability to use an acceptable contraceptive method for the entire study period and for at least 3 months after study completion.
- •Women are not regarded as of childbearing potential if they are post-menopausal (at least 2 years without menses) or are surgically sterile (at least 1 month before study).
- •Acceptable contraception c
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Open-Label clinical trial of the drug Quizartinib (AC220) compared to recovery treatment in patients with Acute Myeloid Leukemia (AML), a cancer of the blood.Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML)MedDRA version: 20.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2013-004890-28-PLDaiichi Sankyo Inc367
已完成
3 期
A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation(HSCT) Consolidation.LeukemiaNL-OMON45222Daiichi Sankyo, Inc.20
进行中（未招募）
1 期
A Phase 3 Open-Label clinical trial of the drug Quizartinib (AC220) compared to recovery treatment in patients with Acute Myeloid Leukemia (AML), a cancer of the blood.Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML)MedDRA version: 19.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2013-004890-28-CZDaiichi Sankyo Inc.367
进行中（未招募）
1 期
A Phase 3 Open-Label clinical trial of the drug Quizartinib compared to recovery treatment in patients with Acute Myeloid Leukemia (AML), a cancer of the blood.Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML)MedDRA version: 20.0 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864EUCTR2013-004890-28-DEDaiichi Sankyo Inc.367
进行中（未招募）
1 期
A Phase 3 Open-Label clinical trial of the drug Quizartinib compared to recovery treatment in patients with Acute Myeloid Leukemia (AML), a cancer of the blood.Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML)EUCTR2013-004890-28-BEDaiichi Sankyo Inc367